Immunotherapy is Effective in Metastatic Cancer
Yes, immunotherapy is highly effective for metastatic cancer across multiple tumor types, with checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) demonstrating significant improvements in overall survival, progression-free survival, and durable long-term responses compared to chemotherapy alone. 1, 2, 3
Evidence Across Cancer Types
Melanoma (Strongest Evidence)
Immunotherapy has revolutionized metastatic melanoma treatment with the most robust data:
- Nivolumab monotherapy improved overall survival compared to chemotherapy in CheckMate 066 (HR 0.59), with survival curves suggesting long-term survival in at least 50% of patients 1
- Pembrolizumab demonstrated superior OS compared to ipilimumab in KEYNOTE-006, with efficacy independent of dose level (2 mg/kg vs 10 mg/kg) 1
- Ipilimumab plus nivolumab combination provides the highest response rates (~45-50% durable responses) though with slower onset than targeted therapy 3
The 2020 ESMO consensus strongly recommends immunotherapy as first-line for most metastatic melanoma patients, particularly those who can tolerate the initial months of treatment to allow immune response development 3.
Non-Small Cell Lung Cancer
The 2018 SITC consensus established immunotherapy as standard for metastatic NSCLC:
- Nivolumab improved median OS in previously treated squamous NSCLC (9.2 vs 6.0 months; HR 0.59; p<0.001) 4
- Pembrolizumab is approved both as first-line monotherapy and second-line therapy based on demonstrated survival advantages 4
- PD-L1 testing should be routine for all newly diagnosed advanced NSCLC to guide treatment selection 4
Bladder/Urothelial Carcinoma
Pembrolizumab is the only agent with Level A evidence showing significant survival advantage over chemotherapy in the KEYNOTE-045 trial (median OS 10.3 vs 7.4 months, HR 0.73, p=0.0022) 5. This represents regular FDA approval as second-line therapy and accelerated approval as frontline therapy in cisplatin-ineligible patients 5.
Head and Neck Cancer
For recurrent/metastatic HNSCC with platinum-refractory disease, single-agent pembrolizumab or nivolumab are recommended regardless of PD-L1 expression 6. For nasopharyngeal carcinoma, adding anti-PD-1 therapy (toripalimab, camrelizumab, or tislelizumab) to gemcitabine-cisplatin significantly improved PFS (11.7 vs 8.0 months; HR 0.52) 6.
Renal Cell Carcinoma
First-line combination of ICI plus VEGFR TKI is now standard for metastatic clear cell RCC, with strong evidence supporting benefits over single-agent approaches 7.
Key Clinical Considerations
When Immunotherapy Works Best
- Low-volume, asymptomatic disease: Allows time for durable immune response to develop 3
- Normal or mildly elevated LDH: Better prognostic indicator for response 3
- Absence of rapidly progressive disease: Immunotherapy requires weeks to months for response 3
When to Consider Alternatives
For BRAF-mutated melanoma with symptomatic or rapidly progressing disease, targeted therapy may be preferred initially due to faster response kinetics, though immunotherapy provides superior long-term durability 3.
Durability of Response
The defining advantage of immunotherapy is response durability. Unlike chemotherapy where responses are typically transient, immunotherapy can provide long-term disease control even after treatment discontinuation 2, 3. In melanoma, approximately 45-50% of patients achieve durable clinical responses 3.
Safety Profile
Immunotherapy toxicity differs fundamentally from chemotherapy:
- Immune-related adverse events (irAEs) occur in <20% of patients with most being grade 1-2 8
- Treatment discontinuation due to toxicity ranges from 5-21% across studies 8
- Critical caveat: Requires experienced clinician recognition and management of irAEs, which can affect any organ system 5, 8
Biomarker Considerations
PD-L1 expression helps identify patients more likely to respond but is not absolute:
- High PD-L1 expression correlates with better response rates 4, 5
- Durable responses occur even in PD-L1 low/negative patients, albeit at lower frequencies 5
- MSI-H/dMMR status predicts response across tumor types (39.6% response rate in pembrolizumab trials) 5
Common Pitfall to Avoid
Do not dismiss immunotherapy based solely on initial imaging showing stable or minimal response. Immune-related response patterns differ from chemotherapy, with responses potentially developing over prolonged periods. Continue treatment through initial "pseudoprogression" unless clear clinical deterioration occurs 9.